SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Daneng Li, Eileen M. O’Reilly, Adjuvant and Neoadjuvant Systemic Therapy for Pancreas Adenocarcinoma, Seminars in Oncology, 2015, 42, 1, 134

    CrossRef

  2. 2
    Lauren E. Colbert, Sarah B. Fisher, Serdar Balci, Burcu Saka, Zhengjia Chen, Sungjin Kim, Bassel F. El-Rayes, N. Volkan Adsay, Shishir K. Maithel, Jerome C. Landry, Walter J. Curran, High Nuclear Hypoxia-Inducible Factor 1 Alpha Expression Is a Predictor of Distant Recurrence in Patients With Resected Pancreatic Adenocarcinoma, International Journal of Radiation Oncology*Biology*Physics, 2015, 91, 3, 631

    CrossRef

  3. 3
    Marçal Pastor-Anglada, Sandra Pérez-Torras, Nucleoside transporter proteins as biomarkers of drug responsiveness and drug targets, Frontiers in Pharmacology, 2015, 6,

    CrossRef

  4. 4
    Y Aye, M Li, M J C Long, R S Weiss, Ribonucleotide reductase and cancer: biological mechanisms and targeted therapies, Oncogene, 2015, 34, 16, 2011

    CrossRef

  5. 5
    Boin Lee, Sang Yun Ha, Dae Hyun Song, Hyun Woo Lee, Soo Youn Cho, Cheol-Keun Park, High Expression of Ribonucleotide Reductase Subunit M2 Correlates with Poor Prognosis of Hepatocellular Carcinoma, Gut and Liver, 2014, 8, 6, 662

    CrossRef

  6. 6
    Mina Maftouh, Amir Avan, Niccola Funel, Adam E. Frampton, Hamid Fiuji, Serena Pelliccioni, Leandro Castellano, Valentina Galla, Godefridus J. Peters, Elisa Giovannetti, miR-211 Modulates Gemcitabine Activity Through Downregulation of Ribonucleotide Reductase and Inhibits the Invasive Behavior of Pancreatic Cancer Cells, Nucleosides, Nucleotides and Nucleic Acids, 2014, 33, 4-6, 384

    CrossRef

  7. 7
    W. Greenhalf, P. Ghaneh, J. P. Neoptolemos, D. H. Palmer, T. F. Cox, R. F. Lamb, E. Garner, F. Campbell, J. R. Mackey, E. Costello, M. J. Moore, J. W. Valle, A. C. McDonald, R. Carter, N. C. Tebbutt, D. Goldstein, J. Shannon, C. Dervenis, B. Glimelius, M. Deakin, R. M. Charnley, F. Lacaine, A. G. Scarfe, M. R. Middleton, A. Anthoney, C. M. Halloran, J. Mayerle, A. Olah, R. Jackson, C. L. Rawcliffe, A. Scarpa, C. Bassi, M. W. Buchler, Pancreatic Cancer hENT1 Expression and Survival From Gemcitabine in Patients From the ESPAC-3 Trial, JNCI Journal of the National Cancer Institute, 2014, 106, 1, djt347

    CrossRef

  8. 8
    Amir Avan, Mina Maftouh, Elisa Giovannetti, An analysis of human equilibrative nucleoside transporter-1, ribonucleoside reductase subunit M1, ribonucleoside reductase subunit M2, and excision repair cross-complementing gene-1 expression in patients with resected pancreas adenocarcinoma: Implications for adjuvant treatment, Cancer, 2013, 119, 14
  9. 9
    Malcolm H. Squires, Sarah B. Fisher, Kevin E. Fisher, Sameer H. Patel, David A. Kooby, Bassel F. El-Rayes, Charles A. Staley, Alton B. Farris, Shishir K. Maithel, Differential expression and prognostic value of ERCC1 and thymidylate synthase in resected gastric adenocarcinoma, Cancer, 2013, 119, 17
  10. 10
    Lars Petter Jordheim, Charles Dumontet, Do hENT1 and RRM1 predict the clinical benefit of gemcitabine in pancreatic cancer?, Biomarkers in Medicine, 2013, 7, 4, 663

    CrossRef

  11. 11
    Jun-Feng Zhang, Rong Hua, Yong-Wei Sun, Wei Liu, Yan-Miao Huo, De-Jun Liu, Jiao Li, Influence of Perineural Invasion on Survival and Recurrence in Patients with Resected Pancreatic Cancer, Asian Pacific Journal of Cancer Prevention, 2013, 14, 9, 5133

    CrossRef

  12. 12
    Lauren E. Colbert, Sarah B. Fisher, Claire W. Hardy, William A. Hall, Burcu Saka, Joseph W. Shelton, Aleksandra V. Petrova, Matthew D. Warren, Brooke G. Pantazides, Khanjan Gandhi, Jeanne Kowalski, David A. Kooby, Bassel F. El-Rayes, Charles A. Staley, N. Volkan Adsay, Walter J. Curran, Jerome C. Landry, Shishir K. Maithel, David S. Yu, Pronecrotic mixed lineage kinase domain-like protein expression is a prognostic biomarker in patients with early-stage resected pancreatic adenocarcinoma, Cancer, 2013, 119, 17
  13. 13
    Sarah B. Fisher, Shishir K. Maithel, Reply to an analysis of human equilibrative nucleoside transporter-1, ribonucleoside reductase subunit M1, ribonucleoside reductase subunit M2, and excision repair cross-complementing gene-1 expression in patients with resected pancreas adenocarcinoma: Implications for adjuvant treatment, Cancer, 2013, 119, 14
  14. 14
    Jimin Shao, Xiyong Liu, Lijun Zhu, Yun Yen, Targeting ribonucleotide reductase for cancer therapy, Expert Opinion on Therapeutic Targets, 2013, 17, 12, 1423

    CrossRef